Baxter
SpecialtyBaxter is a specialty pharmaceutical company focused on Infectious Disease, Cardiovascular, Oncology. Key products include EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE.
Baxter at a Glance
- Strong track record with 82% execution quality across 25 trials
- Fast trial execution (8 months median completion)
Baxter's Key Drugs
Baxter's core commercial portfolio centers on DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Breast Cancer
Simple dental procedures
Gastroesophageal Reflux Disease
Complicated Skin and Skin Structure Infections
Hypotension
Baxter's Recent FDA Approvals
Baxter secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Baxter's Therapeutic Areas
Baxter's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 4 biologic and 33 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Baxter's Top Competitors
Baxter's closest competitors by therapeutic-area and drug-target overlap include Merck, Sanofi, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Baxter Pipeline Snapshot
Baxter has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (9)
Discontinued (3)
Company Info
- First Approval
- 1951-12-29
- Latest
- 2026-06-11
- Applications
- 228
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges